Second of the two phase I bioequivalence trials of once-daily extended release formulation of lorcaserin in healthy adults

Trial Profile

Second of the two phase I bioequivalence trials of once-daily extended release formulation of lorcaserin in healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Lorcaserin (Primary) ; Lorcaserin
  • Indications Obesity
  • Focus Pharmacokinetics; Registrational
  • Sponsors Arena Pharmaceuticals; Eisai Inc
  • Most Recent Events

    • 27 Sep 2016 Results assessing pharmacokinetics published in the Clinical Therapeutics.
    • 20 Jul 2016 According to Eisai media release, based on results of this and another phase I trial (CTP 700255707) the US FDA has approved a New Drug Application (NDA) for lorcaserin for chronic weight management.
    • 30 Nov 2015 According to Eisai Inc media release, the US FDA has accepted for filling the New Drug Application (NDA) for extended release lorcaserin based on results of this and another phase I trial (CTP 700255707).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top